Clinical Trial: Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study
Study Status: Completed
Recruit Status: Unknown status
Study Type: Interventional
Official Title: Tazarotene 0.1% Cream For the Treatment of Cutaneous T-Cell Lymphoma: A Prospective Study
Brief Summary: This is an open label, prospective study to evaluate therapeutic potential of Tazarotene 0.1% cream for the treatment of Stage I-IIA CTCL. Patients with Stage I-IIA disease are enrolled into the study. Tazarotene will be used for up to 24 weeks and patients will be followed for up to 12 months.
Detailed Summary:
Sponsor: McGill University
Current Primary Outcome: Partial response (PR) is defined as some improvement (25%-50%);significant evidence of disease remains or disease has not changed from baseline condition (<25%);no new clinically abnormal(>1.5 cm)lymph nodes,<25% progression of existence
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: McGill University
Dates:
Date Received: October 22, 2008
Date Started: October 2008
Date Completion: December 2012
Last Updated: October 22, 2008
Last Verified: October 2008